Rein Therapeutics Inc (RNTX) Key Metrics
RNTX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $50.9M
- Enterprise value
- $66.9M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 6.5 10-yr median 1.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.35
RNTX key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRNTX valuation Price multiples at each fiscal year-end price.
RNTX returns How much profit the business earns on the capital it uses.
RNTX per-share figures Results divided by the shares outstanding at year-end.
RNTX financial health Debt, liquidity and how easily interest is covered.
RNTX efficiency & capital use Working capital cycle and where the cash goes.
RNTX valuation history
RNTX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RNTX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RNTX price vs earnings per share
RNTX key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $29.5M | $41.3M | — | — | — | $362.6M |
| Enterprise value | $26.3M | $28.4M | — | — | — | $349.2M |
| Price / book | 1.7 | 0.8 | — | — | — | 29.8 |
| Earnings yield | −169.0% | −152.4% | — | — | — | −0.0% |
| Free cash flow yield | −65.6% | −54.0% | — | — | — | −5.6% |
| Share price at fiscal year-end | $1.16 | $2.30 | $3.05 | $2.37 | $11.26 | $20.80 |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | — | — | — | $0.00 |
| Earnings per share | −$1.96 | −$3.51 | — | — | — | −$0.00 |
| Operating cash flow per share | −$0.76 | −$1.24 | — | — | — | −$1.17 |
| Free cash flow per share | −$0.76 | −$1.24 | — | — | — | −$1.17 |
| Cash per share | $0.13 | $0.72 | — | — | — | $0.79 |
| Book value per share | $0.66 | $3.03 | — | — | — | $0.70 |
| Tangible book value per share | −$0.11 | −$0.03 | — | — | — | $0.70 |
| Capex per share | $0.00 | $0.00 | — | — | — | $0.00 |
| Debt per share | — | — | — | — | — | $0.02 |
| Shares outstanding | 25.4M | 17.9M | — | — | — | 17.4M |
| Change in shares outstanding | +41.8% | — | — | — | — | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −139.9% | −205.2% | −0.1% | −0.1% | −0.1% | −0.2% |
| Return on invested capital (ROIC) | −62.7% | −330.3% | — | — | — | — |
| Return on assets (ROA) | −106.8% | −71.8% | −0.0% | −0.1% | −0.1% | −0.1% |
| Return on tangible assets | — | −437.3% | −0.1% | −0.1% | −0.1% | −0.1% |
| Financial health | ||||||
| Total debt | — | — | $48,000 | $33,000 | $162,000 | $387,000 |
| Cash & short-term investments | $3.2M | $12.9M | $17.3M | $21.2M | $45.9M | $13.8M |
| Net debt | −$3.2M | −$12.9M | −$17.3M | −$21.2M | −$45.8M | −$13.4M |
| Debt / equity | — | — | 0.01 | 0.00 | 0.00 | 0.03 |
| Debt / assets | — | — | 0.00 | 0.00 | 0.00 | 0.02 |
| Net debt / EBITDA | — | — | −166.57 | −149.71 | — | — |
| Current ratio | 0.70 | 2.38 | 4.17 | 6.46 | 10.69 | 4.12 |
| Quick ratio | 0.70 | 2.38 | 4.17 | 6.46 | 10.69 | 4.12 |
| Working capital | −$1.9M | $7.9M | $13.9M | $18.5M | $43.7M | $12.4M |
| Invested capital | $13.7M | $41.5M | −$10.4M | −$2.6M | −$1.9M | −$1.3M |
| Tangible asset value | −$2.9M | −$468,000 | −$78.6M | $18.6M | $43.9M | $12.2M |
| Net current asset value | −$2.9M | −$1.2M | −$80.9M | $18.5M | $43.6M | $12.1M |
| Graham net-net per share | −$0.16 | −$0.11 | — | — | — | $0.55 |
| Capital allocation | ||||||
| Capex / depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 1.30 | 0.03 |
| Efficiency | ||||||
| Days payables outstanding | 891,877.5 | 6,086.2 | — | — | — | — |
| Payables turnover | 0.00 | 0.06 | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $2.4M | $1.1M | $1.5M | $1.5M | $1.4M | $1.6M |
| Intangibles / total assets | 82.1% | 79.2% | 80.7% | 0.0% | 0.0% | 0.0% |
Computed from RNTX's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RNTX valuation and financial ratios
Rein Therapeutics earned a return on equity of −139.9% and a return on invested capital of −62.7% in fiscal 2025. The share count rose 46.0% from 17.4M to 25.4M over 5 years.
See the RNTX income statement, the RNTX chart for price history, or the RNTX stock overview for the latest quote and news.
RNTX key metrics FAQ
What is Rein Therapeutics's return on equity?
Rein Therapeutics's return on equity (ROE) was −139.9% in fiscal 2025: net income of -$49.9 million on average shareholders' equity of $35.7 million.
What is Rein Therapeutics's ROIC?
Rein Therapeutics's return on invested capital was −62.7% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is Rein Therapeutics's free cash flow yield?
Rein Therapeutics generated -$19.4 million of free cash flow in fiscal 2025, a free cash flow yield of −65.6% on its market value at year-end ($29.5 million).
What is Rein Therapeutics's current ratio?
Rein Therapeutics's current ratio was 0.70 at the end of fiscal 2025: current assets were 0.70 times current liabilities.